Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolution of beta-lactamase inhibitors.

G N Rolinson1

  • 1Research Division, Beecham Pharmaceuticals, Betchworth, Surrey, England.

The Journal of Reproductive Medicine
|June 1, 1988
PubMed
Summary

Beta-lactamase enzymes confer antibiotic resistance by inactivating beta-lactam drugs. Combining clavulanic acid with antibiotics like amoxicillin overcomes this resistance, restoring efficacy against problematic bacterial strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 50th anniversary of the discovery of 6-aminopenicillanic acid (6-APA).

International journal of antimicrobial agents·2006
Same author

Forty years of beta-lactam research.

The Journal of antimicrobial chemotherapy·1998
Same author

A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993.

Journal of chemotherapy (Florence, Italy)·1994
Same author

A clarithromycin sensitivity survey.

The Journal of antimicrobial chemotherapy·1994
Same author

Evolution of beta-lactamase inhibitors.

Reviews of infectious diseases·1991
Same author

Evolution of beta-lactamase inhibitors.

Surgery, gynecology & obstetrics·1991

Area of Science:

  • Microbiology
  • Biochemistry
  • Pharmacology

Background:

  • Beta-lactamase enzymes are bacterial resistance mechanisms.
  • These enzymes inactivate critical antibiotic classes like penicillins and cephalosporins.
  • Resistance mediated by beta-lactamase can spread between bacterial species.

Observation:

  • Common bacteria such as Staphylococcus aureus, Klebsiella, and Pseudomonas aeruginosa frequently produce beta-lactamase.
  • Beta-lactamase enzymes can be located extracellularly or within the periplasmic space.
  • Clavulanic acid acts as a potent inhibitor of beta-lactamase enzymes.

Findings:

  • Clavulanic acid effectively blocks the active site of beta-lactamase.
  • Co-administration of clavulanic acid with amoxicillin or ticarcillin broadens their antibacterial spectrum.
  • This combination therapy is effective against bacteria resistant to single antibiotic agents.

Implications:

  • Clavulanic acid restores the utility of beta-lactam antibiotics against resistant pathogens.
  • This strategy is crucial for treating infections caused by beta-lactamase-producing bacteria.
  • The use of beta-lactamase inhibitors is vital in combating rising antibiotic resistance.

Related Experiment Videos